APTITUDE HEALTH®

EPICS

CONGRESS COVERAGE: ASCO/EHA 2021 – FOCUS ON MULTIPLE MYELOMA

Wednesday, June 23, 2021

FULL REPORT

REPORT CONTENTS

EPICS

MEETING SNAPSHOT

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
June 23, 2021



SELECTED ASCO AND EHA 2021 ABSTRACT PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in multiple myeloma

- 3 from US
- 4 from Europe

MULTIPLE MYELOMA-SPECIFIC DISCUSSIONS on latest research updates, therapeutic advances, and their application in clinical decision-making

PANEL CONSISTING OF 3 US AND 4 EUROPEAN MULTIPLE MYELOMA EXPERTS

EPICS

Gareth Morgan, MD, PhD
NYU Langone

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Sagar Lonial, MD, FACP
Winship Cancer Institute of
Emory University

Niels van de Donk, MD, PhD
Amsterdam University Medical Center

Hermann Einsele, MD, FRCP
University Hospital Würzburg

Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and
Sorbonne University

CHAIR:
María-Victoria Mateos, MD, PhD
University of Salamanca

APTITUDE HEALTH®

MEETING AGENDA

EPICS

Time (CEST)	Topic	Speaker/Moderator
16.00 – 16.05	Welcome and Introductions	María-Victoria Mateos, MD, PhD
16.05 – 16.15	First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma	Irene Ghobrial, MD
16.15 – 16.30	Discussion and Key Takeaways	
16.30 – 16.40	First Line (2): Induction in Transplant-Eligible Multiple Myeloma	Mohamad Mohty, MD, PhD
16.40 – 16.55	Discussion and Key Takeaways	
16.55 – 17.05	First Line (3): Maintenance and MRD	Sagar Lonial, MD, FACP
17.05 – 17.20	Discussion and Key Takeaways	
17.20 – 17.30	R/R MM: First and Second Relapse	María-Victoria Mateos, MD, PhD
17.30 – 17.50	Discussion and Key Takeaways	
17.50 – 17.55	Break	
17.55 – 18.05	Triple-Refractory R/R MM: Novel Agents	Niels van de Donk, MD, PhD
18.05 – 18.25	Discussion and Key Takeaways	
18.25 – 18.35	Triple-Refractory R/R MM: Antibodies and Bispecifics	Hermann Einsele, MD, FRCP
18.35 – 18.55	Discussion and Key Takeaways	
18.55 – 19.05	Triple-Refractory R/R MM: CAR Ts	Gareth Morgan, MD, PhD
19.05 – 19.25	Discussion and Key Takeaways	
19.25 – 19.30	Summary and Closing Remarks	María-Victoria Mateos, MD, PhD

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma

OS AND PFS UPDATES FROM THE MAIA TRIAL: DARA-RD VS RD IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EPICS

FACON T, ET AL. 2021, EHA LB1901

STUDY POPULATION

> NDMM ineligible for high-dose chemotherapy and autologous

OS (A) AND PFS (B) WITH D-Rd VS Rd

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
First Line (2): Induction in Transplant-Eligible Multiple Myeloma

CARDAMON TRIAL: ASCT VS KCd CONSOLIDATION WITH K MAINTENANCE IN NDTE MULTIPLE MYELOMA

YONG K, ET AL. 2021, ASCO 8000

EPICS

STUDY POPULATION

PFS BY RANDOMIZATION ARM

SUBGROUP ANALYSIS OF THE FORTE TRIAL: EFFICACY OF KRd ± ASCT AND K ± R MAINTENANCE IN HIGH-RISK PATIENTS

EPICS

GAY F, ET AL. 2021, ASCO 8002 (EHA S182)

STUDY POPULATION

> MM patients were randomized to KRd_ASCT vs KCd_ASCT vs

PFS OF KRd_ASCT VS KRd12 VS KCd_ASCT

APTITUDE HEALTH®

RESULTS OF THE UK optimum/MUKnine TRIAL: ULTRA HIGH-RISK (UHiR) NDMM PATIENTS TREATED WITH DARA-CVRd

EPICS

KAISER MF, ET AL. 2021, ASCO 8001 (EHA S181)

STUDY POPULATION

- UHiR NDMM patients received Dara-CVRd, V-HD-MEL + ASCT,

CENTRAL RESPONSE RESULTS

APTITUDE HEALTH®

INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL: FRONTLINE ISA-KRD IN HIGH-RISK MULTIPLE MYELOMA PATIENTS

EPICS

LEYPOLDT L, ET AL. 2021, EHA S183

STUDY POPULATION

> HR NDMM patients received Isa-KRd, ASCT (TE patients; Arm A)

PFS OF INTERIM ANALYSIS POPULATION (46 PATIENTS ARM A AND 4 PATIENTS ARM B)



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
First Line (3): Maintenance and MRD

CASSIOPEIA PART 2: DARATUMUMAB MAINTENANCE AFTER VTd ± DARA AND ASCT IN NDMM PATIENTS

EPICS

LEYPOLDT L, ET AL. 2021, ASCO 8004 (EHA S180)

STUDY POPULATION

> TE NDMM patients were randomized to D-VTd or VTd (Part 1;

PFS OF INDUCTION AND MAINTENANCE THERAPY RANDOMIZATION

FINAL ANALYSIS OF LYRA TRIAL: EFFICACY OF DARATUMUMAB IN COMBINATION WITH CyBorD AND AS MAINTENANCE THERAPY

EPICS

RIFKIN R, ET AL. 2021, ASCO 8035 (EHA EP969)

STUDY POPULATION

- Patients with MM and ≤1 prior line of therapy received induction

EFFICACY OUTCOMES

APTITUDE HEALTH®

RESULTS FROM BMT CTN 1302: MAINTENANCE IXAZOMIB AFTER alloHCT FOR HIGH-RISK MULTIPLE MYELOMA

EPICS

NISHIHORI T, ET AL. 2021, ASCO 7003

STUDY POPULATION

- Patients with HR MM received allogeneic HCT and were

PFS AND OS POST-RANDOMIZATION

APTITUDE HEALTH®

MRD EVALUATION DURING IXAZOMIB MAINTENANCE OF MM PATIENTS ENROLLED IN TOURMALINE-MM3 AND -MM4

EPICS

PAIVE B, ET AL. 2021, EHA S184

STUDY POPULATION

> MRD evaluation of patients from the TOURMALINE-MM3 AND

PFS ACCORDING TO EVOLVING MRD KINETICS

CIRCULATING TUMOR CELLS (CTC) AS A DIAGNOSTIC BIOMARKER IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

EPICS

GARCÉS JJ, ET AL. 2021, EHA S185

STUDY POPULATION

> CTCs in peripheral blood at diagnosis and MRD in BM were

OPTIMAL CUTOFFS FOR RISK-STRATIFICATION USING CTCs

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
R/R MM: First and Second Relapse

FINAL ANALYSIS OF TOURMALINE-MM1: IRd VS PLACEBO-Rd IN RRMM PATIENTS

EPICS

GARCÉS JJ, ET AL. 2021, EHA EP963

OS IN ITT POPULATION AND IN PATIENTS WITH HR

IXA-DEX VS POM-DEX IN LENALIDOMIDE-REFRACTORY, PI-EXPOSED MM PATIENTS

DIMOPOULOS M, ET AL. 2021, ASCO 8020

EPICS

DARIA TRIAL: SAFETY AND EFFICACY OF DARATUMUMAB + IXA-DEX IN RRMM PATIENTS AFTER FRONTLINE LENALIDOMIDE

EPICS

TERPOS E, ET AL. 2021, EHA EP1014

STUDY POPULATION

- [redacted]

OUTCOMES

- [redacted]

EXPERT CONCLUSIONS

[redacted]

BOSTON TRIAL SUBGROUP ANALYSIS: SURVIVAL AMONG OLDER PATIENTS TREATED WITH XVd

FACON T, ET AL. 2021, ASCO 8019 (EHA EP976)

EPICS

UPDATES FROM ICARIA-MM: ISATUXIMAB AND LOW-DOSE Pd vs Pd IN RRMM

EPICS

RICHARDSON P, ET AL. 2021, ASCO 8017 (EHA S186)

STUDY POPULATION

- [illegible]

OUTCOMES

- [illegible]

EXPERT CONCLUSIONS

[illegible]

IKEMA SUBGROUP ANALYSIS: ISA-Kd IN RRMM PATIENTS ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS

EPICS

HAJEK R, ET AL. 2021, ASCO 8034

STUDY POPULATION

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
Triple-Refractory R/R MM: Novel Agents

EFFECTS OF XVd (BOSTON TRIAL) AND Xd (STORM TRIAL) ON *RAS*-MUTATED RRMM

EPICS

WALKER CJ, ET AL. 2021, ASCO 8027

STUDY POPULATION

PFS AND OS of *RAS*^{mut} PATIENTS

STOMP TRIAL: SAFETY AND DOSING OF WEEKLY XKd IN CARFILZOMIB-NONREFRACTORY, PRETREATED MM PATIENTS

EPICS

GASPARETTO C, ET AL. 2021, ASCO 8038 (EHA S188)

STUDY POPULATION

XKd RESPONSE RATES

CC-220-MM-001 TRIAL ANALYSIS: IberDd vs IberVd vs IberKd IN RRMM PATIENTS

EPICS

LONIAL S, ET AL. 2021, EHA S187

STUDY POPULATION

STUDY POPULATION BASELINE CHARACTERISTICS

POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES: MELFLUFEN + DEX IN ALKYLATOR-EXPOSED RRMM PATIENTS

RODRÍGUEZ-OTERO P, ET AL. 2021, ASCO 8048

EPICS

STUDY POPULATION

EFFICACY BY SUBGROUPS

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
Triple-Refractory R/R MM: Antibodies and Bispecifics

LocoMMotion: NON-INTERVENTIONAL STUDY OF CURRENT STANDARDS OF CARE IN HEAVILY PRETREATED RRMM PATIENTS

EPICS

MATEOS MV, ET AL. 2021, ASCO 8041

STUDY POPULATION

EFFICACY BY SUBGROUPS



EFFICACY AND SAFETY OF SUBCUTANEOUS ELRANATAMAB (PF-06863135), A BCMA × CD3 BISPECIFIC ANTIBODY, IN RRMM PATIENTS

EPICS

BAHLIS NJ, ET AL. 2021, ASCO 8006 (EHA S192)

STUDY POPULATION

RESPONSE BY DOSING



UPDATED RESULTS FOR TECLISTAMAB, BCMA × CD3 BISPECIFIC ANTIBODY IN RRMM

KRISHNAN AY, ET AL. 2021, ASCO 8007 (EHA S193)

EPICS

STUDY POPULATION

ORR

APTITUDE HEALTH®

UPDATED RESULTS OF TALQUETAMAB, A GPRC5D × CD3 BISPECIFIC ANTIBODY IN RRMM

EPICS

BERDEJA JG, ET AL. 2021, ASCO 8008 (EHA S191)

STUDY POPULATION

ORR

APTITUDE HEALTH®

EPICS

CONGRESS HIGHLIGHTS
Triple-Refractory R/R MM: CAR Ts

UPDATED RESULTS FROM KarMMa: IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN RRMM

EPICS

ANDERSON LD, ET AL. 2021, ASCO 8016 (EHA EP1009)

STUDY POPULATION

[illegible]

RESPONSE RATES

[illegible]



[illegible]

UPDATED RESULTS FROM CARTITUDE-1: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR T-CELL THERAPY IN RRMM

EPICS

USMANI SZ, ET AL. 2021, ASCO 8005 (EHA EP964)

STUDY POPULATION

PFS



CILTA-CEL VERSUS CONVENTIONAL TREATMENT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA

EPICS

COSTA LJ, ET AL. 2021, ASCO 8030

STUDY POPULATION

EFFICACY RATES

CARTITUDE-2: EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH 1-3 PRIOR LINES OF THERAPY

EPICS

USMANI SZ, ET AL. 2021, ASCO 8005 (EHA EP964)

STUDY POPULATION

DURATION OF RESPONSE

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

KEY INSIGHTS

KEY INSIGHTS: SMOLDERING MULTIPLE MYELOMA

EPICS

SMOLDERING MULTIPLE MYELOMA

KEY INSIGHTS: TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA

EPICS

TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA

KEY INSIGHTS: INDUCTION IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

EPICS

EARLY VS DELAYED TRANSPLANT

APTITUDE HEALTH®

KEY INSIGHTS: MAINTENANCE THERAPY

EPICS

MAINTENANCE THERAPY

lenalidomide for high-risk patients

APTITUDE HEALTH®

KEY INSIGHTS: MRD AND PROGNOSTIC FACTORS

EPICS

MRD AND PROGNOSTIC FACTORS

KEY INSIGHTS: R/R MM – FIRST AND SECOND RELAPSE

EPICS

FIRST AND SECOND RELAPSE

KEY INSIGHTS: TRIPLE-REFRACTORY R/R MM – NOVEL AGENTS

EPICS

NOVEL THERAPIES

KEY INSIGHTS: TRIPLE-REFRACTORY R/R MM – ANTIBODIES AND BISPECIFICS

EPICS

ANTIBODIES AND BISPECIFIC AGENTS

KEY INSIGHTS: TRIPLE-REFRACTORY R/R MM – CAR TS

EPICS

CAR Ts